In focus · trending topic

Asklepion Pharmaceuticals

2 stories · following the connections

Asklepion Pharmaceuticals Announces Special Protocol Assessment (SPA) Agreement with FDA for Phase 3 Program of Intravenous Citrulline

By Nasdaq OMXDec 19, 2017, 2:01 PM UTC

Asklepion Pharmaceuticals Presents Phase 1b/2a Clinical Trial Data for IV-Citrulline at the Pediatric Cardiac Intensive Care Society 13th Annual International Meeting

By Nasdaq OMXDec 8, 2017, 2:00 PM UTC